$RXRX at 52W lows, this isn’t investing, it’s a high-variance liquidity flip. Size it like a moonshot, not a compounder.

Recursion ($RXRX) is the definition of a high-variance play, blending AI with Big Pharma. On Feb 4, 2026, the stock hit a new 52-week low, dipping to $3.71 before closing at $3.90 (-10.76%). This $3.70–$3.90 range has become a high-volume liquidity zone, proving there is zero long-term loyalty here, it is purely about the flip right now. If the tech works, it’s a 10-bagger; if not, it’s a tax-loss harvest candidate. Do not treat this like a safe compounding play. It is a moonshot, so size it accordingly and rely on the data.